UK's Regulatory Agency Backs Pfizer/BioNTech's COVID-19 Vaccine For Youngest Kids

  • The Medicines and Healthcare products Regulatory Agency (MHRA) authorized the vaccine - made by Pfizer Inc PFE and BioNTech SE BNTX for children aged six months to four years old.
  • This decision was endorsed after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants.
  • The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. 
  • Related: Pfizer/BioNTech's Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages.
  • It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.
  • This presentation is designed for this new age group and given at a lower dose than those used in individuals aged 5 to 11 years (3 micrograms compared with 10 micrograms). 
  • The Comirnaty COVID vaccine has met the MHRA's required safety, quality, and effectiveness standards to be authorized for use in this age group.
  • Price Action: PFE shares are down 2.38% at $49.53, and BNTX shares are down 3.96% at $160.10 on the last check Monday.
  • Photo via Wikimedia Commons
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!